<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Trial id="78767"><TitleDisplay>A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants</TitleDisplay><TitleOfficial>A Randomized Clinical Trial to Validate Novel Biomarker Approaches After Single Doses of Anticoagulants in Healthy Young Male Subjects and in Healthy Elderly Subjects</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">MK-0000-216</Identifier><Identifier type="NCT">NCT01379300</Identifier></Identifiers><Indications><Indication id="1076">Thrombosis</Indication></Indications><BiomarkerNames><BiomarkerName id="183" role="Therapeutic effect marker" type="Proteomic">D-dimer</BiomarkerName><BiomarkerName id="358" role="Therapeutic effect marker" type="Genomic;Proteomic">Prothrombin</BiomarkerName><BiomarkerName id="1174" role="Therapeutic effect marker" type="Proteomic">Fibrinopeptide A</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>dabigatran etexilate</Name><Drug id="24343">dabigatran etexilate</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>rivaroxaban</Name><Drug id="32677">rivaroxaban</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="24343">dabigatran etexilate</Drug><IndicationsPioneer><Indication id="1076">Thrombosis</Indication></IndicationsPioneer><Companies><Company><Company id="1059823">Merck Sharp &amp; Dohme Corp</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="32677">rivaroxaban</Drug><IndicationsPioneer/><Companies><Company><Company id="1059823">Merck Sharp &amp; Dohme Corp</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="24343" type="Drug"><TargetEntity id="305702" type="siDrug">Dabigatran etexilate mesilate</TargetEntity></SourceEntity><SourceEntity id="32677" type="Drug"><TargetEntity id="307796" type="siDrug">Rivaroxaban</TargetEntity></SourceEntity><SourceEntity id="1059823" type="Company"><TargetEntity id="4295904507" type="organizationId">Merck Sharp &amp; Dohme Corp</TargetEntity></SourceEntity><SourceEntity id="1076" type="ciIndication"><TargetEntity id="10043607" type="MEDDRA"/><TargetEntity id="D013927" type="MeSH"/><TargetEntity id="304" type="siCondition"/></SourceEntity><SourceEntity id="111" type="Action"><TargetEntity id="502" type="Mechanism">Thrombin Inhibitors</TargetEntity><TargetEntity id="4384" type="Mechanism">Anti-Thrombin</TargetEntity></SourceEntity><SourceEntity id="11192" type="Action"><TargetEntity id="1024" type="Mechanism">PAR1 Antagonists</TargetEntity></SourceEntity><SourceEntity id="120" type="Action"><TargetEntity id="679" type="Mechanism">Coagulation Factor Xa Inhibitors</TargetEntity><TargetEntity id="6421" type="Mechanism">Anti-Factor Xa</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1059823">Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="111">Factor IIa antagonist</Action><Action id="11192">Protease-activated receptor-1 antagonist</Action><Action id="120">Factor Xa antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2953">Anti-inflammatory</Class><Class id="449">Antiarrhythmic agent</Class><Class id="659">Coagulation inhibitor</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="751">Film coating</Technology><Technology id="898">Formulation powder</Technology><Technology id="743">Granule</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="1652">Prodrug</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term></TermsEndpoint><PatientCountEnrollment>42</PatientCountEnrollment><DateStart>2011-05-31T00:00:00Z</DateStart><DateEnd type="actual">2011-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-09-08T05:48:14Z</DateChangeLast><DateAdded>2011-07-05T04:27:02Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Merck Sharp and Dohme B.V.; Bruxelles; 1180; Belgium</Affiliation><Name>Danny Dhulster</Name><Phone>3223734310</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;For non-hemophilia participants:&lt;ul&gt;&lt;li&gt;Panel A:&lt;ul&gt;&lt;li&gt;Male   between 18 to 45 years of age&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Panel B:&lt;ul&gt;&lt;li&gt;Male or female between 65 to 85 years of age&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Both panels:&lt;ul&gt;&lt;li&gt;Weight  &gt;/= 50 kg and&amp;lt;/= 110 kg&lt;/li&gt;&lt;li&gt;In good health&lt;/li&gt;&lt;li&gt;No clinically significant abnormality on electrocardiogram (ECG)&lt;/li&gt;&lt;li&gt;Non-smoker and/or has not used nicotine or nicotine-containing products for at least             approximately 6 months&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;For hemophilia participants:&lt;ul&gt;&lt;li&gt;Male with diagnosis of hemophilia B between 18 to 45 years of age&lt;/li&gt;&lt;li&gt;Weight of &gt;/= 110  and&amp;lt;/= 300 lbs&lt;/li&gt;&lt;li&gt;Has not received clotting factor in the 7 days prior to blood sampling&lt;/li&gt;&lt;li&gt;No active bleeding event&lt;/li&gt;&lt;li&gt;No procedure or surgery in the past 8 weeks&lt;/li&gt;&lt;li&gt;Judged to be in good health based on medical history&lt;/li&gt;&lt;li&gt;Has not smoked more than two cigarettes per day for at least approximately 1 week             prior; has not smoked a pipe or cigar or chewed tobacco for at least 3 days prior&lt;/li&gt;&lt;li&gt;Can refrain from the use of all NSAIDs (eg, Advil, Aleve, aspirin), all             NSAID-containing products (including pain, cold, and allergy products, etc), herbal             meds or drugs for 7 days prior to the date of study procedure&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;For non-hemophilia participants:&lt;ul&gt;&lt;li&gt;History of stroke, chronic seizures, or major neurological disorder&lt;/li&gt;&lt;li&gt;History of clinically significant endocrine, gastrointestinal (including peptic ulcer             disease), cardiovascular, hematological, hepatic, immunological, renal, respiratory,             or  genitourinary abnormalities or diseases&lt;/li&gt;&lt;li&gt;History of malignant neoplastic disease, with the exception of adequately treated             non-melanomatous skin carcinoma or other malignancies that have been successfully             treated greater than or equal to  ten  years prior to the study&lt;/li&gt;&lt;li&gt;History of a thrombotic or platelet-related disorder including prior deep venous             thrombosis or pulmonary embolus&lt;/li&gt;&lt;li&gt;Use of  warfarin, coumadin, heparin, aspirin, dabigatran etexilate,&lt;ulink linkType="Drug" linkID="32677"&gt;rivaroxaban&lt;/ulink&gt; or             dipyridamole within 2 weeks&lt;/li&gt;&lt;li&gt;History of poor wound healing&lt;/li&gt;&lt;li&gt;Unable to refrain from or anticipates the use of any medication, including aspirin             and aspirin-containing products, all non-steroidal anti-inflammatory drug             (NSAID)-containing products (including pain, cold and allergy products, etc) and             including prescription and non-prescription drugs or herbal remedies (such as St             John's Wort [Hypericum perforatum]) beginning approximately 2 weeks (or five half-lives)             prior to initiation of the treatment periods, throughout the study until the             post-study visit&lt;/li&gt;&lt;li&gt;Consumption of excessive amounts of alcohol, defined as greater than three glasses of             alcoholic beverages (one glass is approximately equivalent to: beer [284 ml/10 oz],             wine [125 ml/4 oz], or distilled spirits [25 ml/1 oz]) per day&lt;/li&gt;&lt;li&gt;Consumption of excessive amounts, defined as greater than six servings (one serving is             approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other             caffeinated beverages per day&lt;/li&gt;&lt;li&gt;  Major surgery, donation or loss of one unit of blood (approximately 500 ml) or             participation in another investigational study within 4 weeks&lt;/li&gt;&lt;li&gt;History of significant multiple and/or severe allergies (including latex allergy), or             an anaphylactic reaction or significant intolerability to prescription or             non-prescription drugs or food, including dabigatran etexilate and &lt;ulink linkType="Drug" linkID="32677"&gt;rivaroxaban&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Current regular user (including illicit drugs) or has a history of drug (including             alcohol) abuse within approximately 6 months&lt;/li&gt;&lt;li&gt;History (including family history if hereditary) or symptoms of clinically relevant             bleeding disorder&lt;/li&gt;&lt;li&gt;Organic lesion at risk of bleeding (eg, aneurysm, cavernous hemangioma,             arterio-venous malformation)&lt;/li&gt;&lt;li&gt;History of frequent epistaxis or has recurrent or active gingivitis or hemorrhoids&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;For hemophilia participants:&lt;ul&gt;&lt;li&gt;Clinically significant endocrine, gastrointestinal (including peptic ulcer disease),             cardiovascular, hematological (except factor IX deficiency), immunological, renal,             respiratory, neurological or genitourinary abnormalities or diseases&lt;/li&gt;&lt;li&gt;History of malignant neoplastic disease, with the exception of adequately treated             non-melanomatous skin carcinoma or other malignancies that have been successfully             treated greater than or equal to ten  years prior to the study&lt;/li&gt;&lt;li&gt;Consumption of excessive amounts of alcohol, defined as greater than three  glasses of             alcoholic beverages (one glass is approximately equivalent to: beer [284 ml/10 oz],             wine [125 ml/4 oz], or distilled spirits [25 ml/1 oz]) within 24 h prior             to study procedures&lt;/li&gt;&lt;li&gt;Major surgery, donation or loss of one unit of blood (approximately 500 ml) or             participation in another investigational study within 7 days prior to the date of             study procedures&lt;/li&gt;&lt;li&gt;Current regular user (including illicit drugs) or has a history of drug (including             alcohol) abuse within approximately 6 months&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Endogenous thrombin potential by Thrombin Generation Assay (TGA)-2a assay</Description><Timeframe>From up to 2 h pre-dose to up to 24 h post-dose</Timeframe></Measure><Measure><Description>Level of fibrin degradation product (D-dimer)</Description><Timeframe>From up to 2 h pre-dose to up to 24 h post-dose</Timeframe></Measure><Measure><Description>Level of fibrinopeptide A (FPA)</Description><Timeframe>From up to 2 h pre-dose to up to 24 h post-dose</Timeframe></Measure><Measure><Description>Level of prothrombin split products (F1+2)</Description><Timeframe>From up to 2 h pre-dose to up to 24 h post-dose</Timeframe></Measure><Measure><Description>Level of thrombin-antithrombin complex (TAT)</Description><Timeframe>From up to 2 h pre-dose to up to 24 h post-dose</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a study to investigate biomarkers after single oral doses of the anticoagulant      agents &lt;ulink linkType="Drug" linkID="24343"&gt;dabigatran etexilate&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="32677"&gt;rivaroxaban&lt;/ulink&gt; in healthy young male subjects and in healthy      elderly subjects.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive a single dose of either &lt;ulink linkType="Drug" linkID="24343"&gt;dabigatran etexilate&lt;/ulink&gt; 150 mg po, &lt;ulink linkType="Drug" linkID="32677"&gt;rivaroxaban&lt;/ulink&gt; 20 mg po or no intervention.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hemophilia</Disease><PatientSegments><PatientSegment><PatientSegment id="9880">Subjects with Hemophilia B</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01379300</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Thrombosis" id="10292"><Endpoint>Assessment of Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="Thrombosis" id="10295">Assessment of markers of coagulation/thrombosis</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Hemophilia" id="17980"><Endpoint>Assessment of Blood Coagulation</Endpoint><SubEndpoints><SubEndpoint disease="Hemophilia" id="17983">Assessment of fibrin degradation product</SubEndpoint><SubEndpoint disease="Hemophilia" id="17984">Assessment of fibrinopeptide A (FPA)</SubEndpoint><SubEndpoint disease="Hemophilia" id="17985">Assessment of prothrombin fragment 1+2 (F1+2) levels</SubEndpoint><SubEndpoint disease="Hemophilia" id="17986">Assessment of thrombin antithrombin III complex(TAT)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Hemophilia" id="15921"><Criterion>Subjects with Hemophilia B</Criterion></Inclusion><Inclusion disease="Hemophilia" id="15949"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion></Inclusion><Inclusion disease="Hemophilia" id="15966"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Inclusion><Inclusion disease="Hemophilia" id="15983"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion></Inclusion><Inclusion disease="Thrombosis" id="32564"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="5988">Subjects with normal/acceptable cardiac function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thrombosis" id="34754"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="6026">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Thrombosis" id="7560"><Criterion>Subjects with Diagnosis of Thrombosis</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7562">Subjects with venous thrombosis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="7573"><Criterion>Subjects with Thrombosis Related Complications</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7575">Subjects with pulmonary embolism as a complication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="7578"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7580">Subjects with neurologic/psychiatric disorders</SubCriterion><SubCriterion disease="Thrombosis" id="7581">Subjects with malignancy/tumors</SubCriterion><SubCriterion disease="Thrombosis" id="7583">Subjects with endocrine diseases/disorders</SubCriterion><SubCriterion disease="Thrombosis" id="7588">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion><SubCriterion disease="Thrombosis" id="7590">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="7584"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Thrombosis" id="7585"><Criterion>Subjects co-morbid with vascular disorders/diseases</Criterion></Exclusion><Exclusion disease="Thrombosis" id="7587"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Thrombosis" id="7589"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Thrombosis" id="7591"><Criterion>Subjects co-morbid with immunological disease/disorder</Criterion></Exclusion><Exclusion disease="Thrombosis" id="7616"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7625">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="7630"><Criterion>Subjects on Prior/Concurrent Drug Therapies for Thrombosis</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7631">Subjects on prior/concurrent antithrombotic drugs</SubCriterion><SubCriterion disease="Thrombosis" id="7635">Subjects on prior/concurrent oral medications for thrombosis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="7637"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Thrombosis" id="7824"><Criterion>Subjects with Treatment Related Complications</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7825">Subjects with bleeding manifestations</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hemophilia" id="13194"><Criterion>Subjects with Protocol Specified Clinical Manifestations</Criterion><SubCriteria><SubCriterion disease="Hemophilia" id="13195">Subjects with bleeding episodes</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hemophilia" id="13198"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Hemophilia" id="13199">Subjects with central nervous system diseases/disorders</SubCriterion><SubCriterion disease="Hemophilia" id="13206">Subjects with premalignant/malignant condition</SubCriterion><SubCriterion disease="Hemophilia" id="13213">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hemophilia" id="13200"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Hemophilia" id="13202"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Hemophilia" id="13204"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Hemophilia" id="13205"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Hemophilia" id="13207"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Hemophilia" id="13232"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Hemophilia" id="13251"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Hemophilia" id="13252">Subjects with history of anti-coagulant therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hemophilia" id="26063"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Hemophilia" id="13203">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hemophilia" id="26320"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Hemophilia" id="13217">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hemophilia" id="27094"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Hemophilia" id="13201">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="27105"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7586">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2011-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2011-06-03T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2011-07-05T04:27:02Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial>